CLINICAL TRIALS PROFILE FOR DEXONE 4

All Clinical Trials for Dexone 4

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00004228 ↗	Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma	Completed	Children's Oncology Group	Phase 3	2000-06-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. It is not yet known which regimen of combination chemotherapy is most effective for lymphoblastic lymphoma. PURPOSE: This randomized phase III trial is studying different regimens of combination chemotherapy to compare how well they work in treating children or adolescents with newly diagnosed stage III or stage IV lymphoblastic lymphoma.
NCT00025259 ↗	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Completed	National Cancer Institute (NCI)	Phase 3	2002-09-01	This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.
NCT00025259 ↗	Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease	Completed	Children's Oncology Group	Phase 3	2002-09-01	This randomized phase III trial is studying different chemotherapy regimens given with or without radiation therapy to compare how well they work in treating children with newly diagnosed Hodgkin's disease. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different combinations may kill more cancer cells. Radiation therapy uses high-energy x-rays to damage cancer cells. It is not yet known if chemotherapy is more effective with or without additional chemotherapy and/or radiation therapy in treating Hodgkin's disease.

Clinical Trial Conditions for Dexone 4

Condition Name

Condition Name for Dexone 4
Intervention	Trials
Recurrent Plasma Cell Myeloma	34
Refractory Plasma Cell Myeloma	29
Acute Lymphoblastic Leukemia	19
Plasma Cell Myeloma	14

Condition MeSH

Condition MeSH for Dexone 4
Intervention	Trials
Multiple Myeloma	61
Neoplasms, Plasma Cell	60
Leukemia	43
Precursor Cell Lymphoblastic Leukemia-Lymphoma	40

Clinical Trial Locations for Dexone 4

Trials by Country

Trials by Country for Dexone 4
Location	Trials
Canada	140
Australia	64
New Zealand	28
Puerto Rico	15
Switzerland	9

Trials by US State

Trials by US State for Dexone 4
Location	Trials
Texas	64
Minnesota	61
California	50
Florida	44
Ohio	44

Clinical Trial Progress for Dexone 4

Clinical Trial Phase

Clinical Trial Phase for Dexone 4
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	26
Phase 2/Phase 3	4

Clinical Trial Status

Clinical Trial Status for Dexone 4
Clinical Trial Phase	Trials
Recruiting	48
Completed	31
Active, not recruiting	30

Clinical Trial Sponsors for Dexone 4

Sponsor Name

Sponsor Name for Dexone 4
Sponsor	Trials
National Cancer Institute (NCI)	126
M.D. Anderson Cancer Center	30
Mayo Clinic	24

Sponsor Type

Sponsor Type for Dexone 4
Sponsor	Trials
NIH	127
Other	126
Industry	35

Dexone 4 Market Analysis and Financial Projection

Last updated: April 28, 2026

Dexone 4: What do the clinical-trials signal and market projection indicate?

No actionable patent- or clinical-trials update can be produced for “Dexone 4” from the information provided. “Dexone 4” is not a uniquely identifiable drug name, strength, or salt across jurisdictions, and no sponsor, active ingredient, NDA/BLA/CTA ID, trial registry ID (NCT/EudraCT), target, or regulatory status is supplied. Without an unambiguous product identity, any trial summary or market projection would risk attributing data to the wrong asset.

Which active ingredient and regulatory entity is “Dexone 4”?

“Dexone 4” could refer to multiple things depending on country labeling conventions (brand vs. strength vs. combination product), but there is no information in the prompt that pins it to:

• a specific INN/active ingredient
• a defined dosage form (tablet, injection, oral solution, ophthalmic, etc.)
• a route of administration
• a regulatory identifier (US FDA application, EMA EPAR, MHRA, etc.)
• a trial registry footprint (NCT/EudraCT/CTIS)

What clinical-trials update can be compiled?

A clinical-trials update requires a stable anchor:

• trial registry IDs (e.g., NCT numbers)
• study phase and design
• enrollment status (ongoing, completed, recruiting)
• top-line endpoints and timelines
• safety signals and dose regimen
• sponsor and sites

No such anchors exist in the prompt, so a compliant, attributable update cannot be compiled.

What market analysis and projection can be forecasted?

A market forecast also requires an unambiguous asset definition:

• indication(s)
• mechanism of action
• patient population and prevalence drivers
• dosing and treatment duration
• comparator set and current standard of care
• pricing and reimbursement geography
• exclusivity and patent/LP status

Since “Dexone 4” is not uniquely identified, no defensible market sizing, share, pricing pathway, or CAGR projection can be produced.

---

Key Takeaways

• A credible clinical-trials update and market projection for “Dexone 4” cannot be generated without a unique asset identity.
• “Dexone 4” is not sufficiently specified to map to trial registries or regulatory market data.

---

FAQs

1) Why can’t a clinical-trials update be provided for “Dexone 4”?
Because the term does not uniquely identify an active ingredient, regulatory product, or trial registry entries needed to compile trial status and endpoints.

2) Can “Dexone 4” market projections be made without knowing the indication?
No. Market size and growth depend on indication, comparator set, dosing, and reimbursement context.

3) What identifiers are typically required to build a defensible trial and market view?
Active ingredient, dosage form, route, strength mapping to regulatory product, and at least one registry identifier (NCT/EudraCT) or regulatory filing reference.

4) Does brand-name ambiguity affect patent and exclusivity mapping?
Yes. Different products can share similar brand naming patterns, changing exclusivity, competitor landscape, and timeline of competitive entry.

5) What is the fastest way to avoid mis-attribution?
Use a unique regulatory or trial identifier tied to the same product label across jurisdictions.

---

References

[1] ClinicalTrials.gov. (n.d.). Search results depend on query. https://clinicaltrials.gov/
[2] European Union Clinical Trials Register. (n.d.). Search results depend on query. https://www.clinicaltrialsregister.eu/
[3] FDA. (n.d.). Drug application and labeling database resources depend on product identifiers. https://www.fda.gov/